Editorial: preclinical data reproducibility for R&D - the challenge for neuroscience.

摘要: The inability to reproduce published findings has been identified as a major issue in science. Reports of only low percentage landmark studies being reproduced at pharmaceutical companies like Bayer (Prinz et al. 2011) gained much interest the scientific community and raised high levels concerns. A more recent analysis from Amgen (Begley Ellis 2012) suggested that those non-reproducible may have an even stronger impact on field than can be reproduced, possibly because remarkable exciting are reported higher journals. Evidently, this is not just problem industry. About half respondents faculty trainees academic MD Anderson Cancer Center, Houston, Texas, had experienced least one episode data survey by Mobley (2013) comparable figures expected neuroscience.